The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

OBJECTIVE: To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6‐month double‐blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal...

Descripción completa

Detalles Bibliográficos
Autores principales: Broessner, Gregor, Reuter, Uwe, Bonner, Jo H., Dodick, David W., Hallström, Yngve, Picard, Hernan, Zhang, Feng, Lenz, Robert A., Klatt, Jan, Mikol, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590156/
https://www.ncbi.nlm.nih.gov/pubmed/32851644
http://dx.doi.org/10.1111/head.13929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590156/
https://www.ncbi.nlm.nih.gov/pubmed/32851644
http://dx.doi.org/10.1111/head.13929

Ejemplares similares